Introduction
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disorder of the central nervous system. Both genetic and environmental factors are likely to contribute to the etiology of the disease. [1, 2] The contribution of genetics to MS is supported by many reports showing familial aggregation of the disease, high concordance rates among twins, and an increased risk among relatives of patients with MS. [3] Genetic susceptibility for MS is significantly associated with the genes associated with the major histocompatibility complex (MHC). [1] It is now clear that HLA-DRB1 * 15:01 is the principal risk allele and the haplotype exerting greatest effect on risk is HLA-DRB1 * 15:01-DQA1 * 01:02-HLA-DQB1 * 06:02. Decades after this discovery genetic variants were identified outside the MHC region which was associated with MS. These include IL7R, IL2RA, CLEC16A, CD226, GPC5, EV15, TYK2, CD58, earlier study of 197 patients and controls had shown nominal association with two variants, rs12708716, and rs763361 related to CLEC 16A and CD226 genes, respectively. [16] A replication study of 110 European risk variants has been recently conducted among Indians. [17] In this study, two-thirds of the tested variants (72/109) showed over-representation of European risk allele in South Asian cases (P < 0.0003). In the remaining, the most associated variant was rs7318477 which maps close to TNFSF13B, the gene for B-cell related protein B-cell activating factor. In this study, we have used a new and larger data set of 300 MS patients and 720 healthy controls and evaluated the role of 10 single nucleotide polymorphisms (SNP's) outside the MHC region which are known to be associated with MS in Europeans.
Materials and Methods

Sample collection
Patients were obtained from the Mangalore demyelinating disease registry. [18] All consecutive patients selected were diagnosed by McDonald criteria. [19] Unrelated controls were spouses or friends who belonged to the same caste and geographical region as patients. The latter was done to match for ancestry and to reduce the risk of confounder effect. [20] Clinical characteristics and demographic features were recorded [ Table 1 ]. This work was done in compliance with the Declaration of Helsinki. The study was approved by the Institutional Ethics Committee. Informed consent was obtained before blood draw.
Single nucleotide polymorphism genotyping A total of 10 nonMHC SNPs were selected for genotyping [ Table 2 ]. SNP genotyping was performed on an ABI7500 real-time polymerase chain reaction (PCR) genotyping platform using predesigned TaqMan SNP genotyping assays (Applied Biosystems Inc., Foster City, CA, USA) as described earlier. [16] In short, 4 µl of normalized genomic DNA (5 ng/ul) was aliquoted to the bottom surface of a MicroAmp ® Optical 96-Well Reaction Plate. The DNA sample was dried down completely by evaporation. Each PCR contained 20 ng DNA, 12.5 µl Taq Man Universal PCR Master Mix (×2), 1.25 µl SNP genotyping assay (×20), 11.25 µl DNase-free water. The PCR conditions were as follows: 60°C for 1 min, 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. After PCR amplification, endpoint plate read was performed using an Applied Biosystems 7500 real-time PCR system. The Sequence Detection System (Applied Biosystems 7500 software v2.0.6) software uses the fluorescence measurements made during the plate read to plot fluorescence (Rn) values based on the signals from each well. The plotted fluorescence signals indicate which alleles are present in each sample.
Statistical methods
The genotyping success rate, Hardy-Weinberg equilibrium, marker heterozygosity, and data analysis were established using PLINK 1.07 statistical software (Center for Human Genetic Research, Massachusetts General Hospital, Cambridge Street, Boston). [21] Results A total of 300 cases and 720 controls were analyzed in this study. All 10 SNP's were in Hardy-Weinberg equilibrium. The average genotyping success rate across the markers was 98%. In this study, the most significant association was seen with rs17824933 (P = 4.2 × 10 − 5 , odds ratio [OR] = 2.24, 95% confidence interval [CI] =1.51-3.33). Two other SNPs which showed a modest association with MS in this study are TMEM39A rs1132200 (P = 0.023, OR = 1.41, CI = 1.05-1.91) and IL2RA rs2104286 (P = 0.04, OR = 1.3, CI = 1.006-1.67). For the remaining SNPs, the risk allele frequency was over-expressed in cases as compared to healthy controls [ Table 3 ]. Overall, the risk allele frequency was similar between Indian and white populations.
Discussion
The SNP's genotyped in this study were selected because of their known risk-modifying effects for MS in white populations. The lower prevalence of MS in nonwhite populations has limited the power of studies evaluating genetic susceptibility. Despite these limitations, recent studies in nonwhite populations have shown similarity for MS risk variants that have been identified in European populations. These include African Americans [22, 23] and South Asian Indians. [16, 17] In this study, CD6 associated SNP showed the strongest association (P = 4.2 × 10 −5
, OR = 2.24, 95% CI = 1.51-3.33) among the variants studied. CD6 is a cell surface scavenger receptor involved in T-cell activation and proliferation, as well as in thymocyte differentiation. CD6 has recently been identified and validated as a risk gene for MS, based on the association of an SNP, rs17824933, located in intron 1. [11] In accordance with results from Spain [24] and European groups, [25] our results have revealed that rs17824933 is significantly associated with an increased disease risk (OR = 2.24). Fine mapping and functional analysis of CD6 gene in Spanish-Basque dataset CLEC 16A  rs6498169  16  IL2RA  rs2104286  10  CD6  rs17824933  11  RGS1  rs2760524  1  TYK2  rs34536443  19  TMEM39A  rs1132200  3  CD58  rs2300747  1  MPHOSPH 9  rs1790100  12  KIF21B  rs12122721  1  IL12A rs4680534 3 SNPs = Single nucleotide polymorphisms, MS = Multiple sclerosis, MHC = Major histocompatibility complex revealed association of rs17824933 and rs11230559 with MS, both of which are strong in LD with each other (r 2 > 0.8). This data reinforce a genetic role for CD6 in susceptibility to MS. [26] Very little has been known about TMEM39A (transmembrane protein 39A). The associated SNP (rs1132200) within this gene causes a nonsynonymous amino acid change (alanine-threonine) at position 487 in the protein. Genome-wide association study on two independent data set identifies TMEM39A as susceptibility loci (rs1132200, P = 3.09 × 10 −8 OR = 1.24) for MS. [27] In a recent study on replication of TMEM39A (rs1132200) . [28] Our data showed nominal association for rs1132200 (P = 0.023, OR = 1.41, CI = 1.05-1.91). In this study, there was also a nominal association for IL2RA gene associated variant rs2104286 (P = 0.04, OR = 1.3, CI = 1.006-1.67). Fine mapping of IL2RA showed that rs2104286 was the most significant SNP in IL2RA region. [7] This gene associated SNP displayed significant associations with MS in a cohort of 1134 patients and 1265 controls from Australia (P = 0.033; OR = 0.86; 95% CI = 0.75-0.99), [29] and case-control, family collections from Europe population (P = 6.27 × 10 − 7 OR of 0.85, 95% CI = 0.79-0.92). [30] Meta-analysis on the two SNPs: rs2104286 and rs12722489 of IL2RA gene showed a positive association between IL2RA gene rs2104286 and MS. [31] Though we failed to find a significant association in the majority of SNP's that were typed, frequency of the latter was more in MS patients as compared to healthy controls. In our previously published study of limited power, CD6 gene associated SNP had shown a trend of association. [16] Our recently published replication study on 110 European risk variants provides evidence that many if not all the MS risk variants identified in populations of European ancestry are likely to also be risk variants in the South Asian population. This study hypothesized that B cells and certain immunoglobulins might play an important role in the pathogenesis of MS in South Asian and other Asian populations in comparison to European MS patients. [17] Our data illustrate the similarity in risk association between Indian and European populations for MS. 
